CAY10594

CAY10594 is an orally active PLD2 inhibitor with an IC₅₀ of 140 nM. CAY10594 has activities such as anti-tumor, anti-oxidation and liver protection. CAY10594 can be used for the research of diseases like breast cancer, acute liver injury and colitis^[1][2][3][4]. In Vitro:CAY10594 (Compound 72) (20 μM; 48 h) inhibits the migration of MDA-231, 4T1, and PMT breast cancer cells^[1].
CAY10594 (10 μM; 7 h) improves LPS (HY-D1056)-induced increased endothelial permeability and decreased transendothelial electrical resistance, inhibits phosphatidic acid production and STAT3 phosphorylation, and enhances the expression of tight junction proteins in HUVECs^[2].
CAY10594 (10 μM; 0-16 h) significantly reduces Acetaminophen (HY-66005)-induced lactate dehydrogenase release and cell death, and blocks GSK-3β phosphorylation in primary hepatocytes^[3]. In Vivo:CAY10594 (1-8 mg/kg; intraperitoneal injection; single dose) exerts a protective effect in a mouse model of acute liver injury^[3].
CAY10594 (4 mg/kg; oral gavage; 10 days) shows ameliorative effects in a mouse model of colitis^[4].